Bruceine E attenuates hepatic steatosis through modulation of PI3K/AKT/NFκB signalling pathway
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Farahdina Man und 3 weiteren Autor:innen. Beteiligte Einrichtung: MedChem Herbal Research Group, Faculty of Pharmacy, Universiti Teknologi MARA, Selangor Branch, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selango…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, NF-kappa B, Non-alcoholic Fatty Liver Disease, Sesquiterpenes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Malaysia Ministry of Higher Education, UiTM Grant.
Abstract (Originalsprache)
Objectives
This study aims to establish the effect of bruceine E in attenuating nonalcoholic steatohepatitis (NASH) through the PI3K/AKT/NFκB pathway.
Methods
High-fat-diet (HFD) male Wistar rats were orally administered with glibenclamide (20 mg/kg) or bruceine E (400, 800, or 1600 µg/kg) for 4 weeks. After 4 weeks of treatment, blood serum was analysed for liver markers. Liver histology was used to identify the degree of inflammation. The liver tissue was evaluated on the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) and inflammatory genes (nuclear factor-kappa B [NFκB], tumor necrosis factor alpha [TNFα], interleukin-6 [IL6], and interleukin-10 [IL10]) and protein expressions. Key findings The alanine transferase and aspartate transferase were reduced in HFD rats administered orally with bruceine E. In liver histology, steatosis, ballooning, and lobular inflammation were alleviated in bruceine E-treated HFD rats. The PI3K/AKT genes and proteins were activated while the inflammatory genes and protein expressions were suppressed in the bruceine E-treated HFD rats showing improvement towards insulin resistance (IR), liver steatosis, and inflammation.
Conclusions
In conclusion, bruceine E attenuated NASH through activation of the PI3K/AKT/NFκB inflammation pathway and may further delay the progression of NASH to hepatocellular carcinoma .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MedChem Herbal Research Group, Faculty of Pharmacy, Universiti Teknologi MARA, Selangor Branch, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor, Malaysia.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Teknologi MARA, 42300 Bandar Puncak Alam, Selangor, Malaysia.
- Department of Basic Sciences in Physiology, Faculty of Health Sciences, Universiti Teknologi MARA, 42300 Bandar Puncak Alam, Selangor, Malaysia.
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.
ORCID-Profile: Chee-Yan Choo
Förderung
- Malaysia Ministry of Higher Education
- UiTM Grant
Zitieren
APA
Man, F., Jayanti, N. E., Leow, C. Y., & Choo, C. Y. (2025). Bruceine E attenuates hepatic steatosis through modulation of PI3K/AKT/NFκB signalling pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf016
Vancouver
Man F, Jayanti NE, Leow CY, Choo CY. Bruceine E attenuates hepatic steatosis through modulation of PI3K/AKT/NFκB signalling pathway. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf016
BibTeX
@article{Man2025,
author = {Man, Farahdina and Jayanti, Neti Eka and Leow, Chiuan Yee and Choo, Chee-Yan},
title = {Bruceine E attenuates hepatic steatosis through modulation of PI3K/AKT/NFκB signalling pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf016}
}
EUVIMED